

## Original Article

# Postarrest Neuroprognostication: Practices and Opinions of Canadian Physicians

Caralyn M. Bencsik<sup>1,2</sup> , Andreas H. Kramer<sup>1,2,3,4</sup>, Philippe Couillard<sup>1,2,3,4</sup>, Maarit MacKay<sup>2</sup> and Julie A. Kromm<sup>1,2,3,4</sup>

<sup>1</sup>Department of Critical Care Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, <sup>2</sup>Alberta Health Services, Calgary, AB, Canada, <sup>3</sup>Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada and <sup>4</sup>Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada

**ABSTRACT: Background:** Objective, evidence-based neuroprognostication of postarrest patients is crucial to avoid inappropriate withdrawal of life-sustaining therapies or prolonged, invasive, and costly therapies that could perpetuate suffering when there is no chance of an acceptable recovery. Postarrest prognostication guidelines exist; however, guideline adherence and practice variability are unknown. **Objective:** To investigate Canadian practices and opinions regarding assessment of neurological prognosis in postarrest patients. **Methods:** An anonymous electronic survey was distributed to physicians who care for adult postarrest patients. **Results:** Of the 134 physicians who responded to the survey, 63% had no institutional protocols for neuroprognostication. While the use of targeted temperature management did not affect the timing of neuroprognostication, an increasing number of clinical findings suggestive of a poor prognosis affected the timing of when physicians were comfortable concluding patients had a poor prognosis. Variability existed in what factors clinicians' thought were confounders. Physicians identified bilaterally absent pupillary light reflexes (85%), bilaterally absent corneal reflexes (80%), and status myoclonus (75%) as useful in determining poor prognosis. Computed tomography, magnetic resonance imaging, and spot electroencephalography were the most useful and accessible tests. Somatosensory evoked potentials were useful, but logistically challenging. Serum biomarkers were unavailable at most centers. Most (79%) physicians agreed  $\geq 2$  definitive findings on neurologic exam, electrophysiologic tests, neuroimaging, and/or biomarkers are required to determine a poor prognosis with a high degree of certainty. Distress during the process of neuroprognostication was reported by 70% of physicians and 51% request a second opinion from an external expert. **Conclusion:** Significant variability exists in post-cardiac arrest neuroprognostication practices among Canadian physicians.

**RÉSUMÉ : Pronostic neurologique à la suite d'un arrêt cardiaque : pratiques et opinions des médecins canadiens. Contexte :** Un pronostic neurologique objectif et fondé sur des données probantes dans le cas de patients ayant été victimes d'un arrêt cardiaque est essentiel pour éviter l'abandon inapproprié de soins essentiels au maintien en vie ou des traitements prolongés, invasifs et coûteux pouvant prolonger la souffrance alors qu'il n'existe aucune chance de guérison acceptable. À cet égard, on peut certes se référer à des lignes directrices dans le cas d'un pronostic neurologique consécutif à un arrêt cardiaque ; cela dit, on ignore dans quelle mesure ces lignes directrices sont respectées et comment varient les pratiques. **Objectif :** Étudier les pratiques et les opinions de médecins canadiens en ce qui regarde l'évaluation des pronostics neurologiques chez des patients ayant subi un arrêt cardiaque. **Méthodes :** Une enquête électronique anonyme a été distribuée aux médecins qui s'occupent de patients adultes victimes d'un arrêt cardiaque. **Résultats :** Sur les 134 médecins qui ont répondu à notre enquête, 63 % d'entre eux n'avaient pas de protocole institutionnel en matière de pronostic neurologique. Bien que l'utilisation d'un dispositif de contrôle ciblé de la température (CCT) n'ait pas affecté le moment où l'on établit un pronostic neurologique, un nombre croissant de constatations cliniques suggérant un mauvais pronostic a affecté le moment où les médecins étaient à l'aise de conclure que leurs patients donnaient à voir un mauvais pronostic. On notera aussi que les facteurs considérés par les cliniciens comme des facteurs de confusion variaient entre eux. Les médecins ont en outre identifié l'absence bilatérale de réflexes pupillaires à la lumière (85 %), l'absence bilatérale de réflexes cornéens (80 %) et les myoclonies (75 %) comme étant utiles pour déterminer un mauvais pronostic. La tomographie par ordinateur, des examens d'IRM et des tests ponctuels d'électroencéphalogramme étaient les modalités diagnostiques les plus utiles et les plus accessibles. Les tests de potentiels évoqués somatosensoriels (PESS) étaient utiles mais posaient des problèmes logistiques. Les biomarqueurs sériques n'étaient pas disponibles dans la plupart des établissements de santé. La plupart des médecins (79 %) ont convenu qu'il fallait plus de deux résultats définitifs à l'examen neurologique, aux tests électrophysiologiques, à la neuro-imagerie et/ou aux biomarqueurs pour déterminer un mauvais pronostic avec un degré élevé de certitude. De plus, 70 % des médecins ont fait part de leur détresse au cours du processus d'établissement d'un pronostic

**Corresponding author:** Julie Anne Kromm; Email: [julie.kromm@ucalgary.ca](mailto:julie.kromm@ucalgary.ca)

**Cite this article:** Bencsik CM, Kramer AH, Couillard P, MacKay M, and Kromm JA. Postarrest Neuroprognostication: Practices and Opinions of Canadian Physicians. *The Canadian Journal of Neurological Sciences*, <https://doi.org/10.1017/cjn.2023.261>

© The Author(s), 2023. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.

neurologique tandis que 51 % d'entre eux ont demandé un deuxième avis à un expert externe. **Conclusion** : Les pratiques des médecins canadiens en matière de pronostic neurologique consécutif à un arrêt cardiaque varient donc considérablement.

**Keywords:** Critical care; brain injury; cardiology

(Received 21 June 2023; date of acceptance 15 July 2023)

## Introduction

Nearly 80% of patients admitted to an intensive care unit post-cardiac arrest are comatose because of hypoxic ischemic brain injury (HIBI). Sixty percent of these patients die following withdrawal of life-sustaining therapies (WLST) because of a predicted poor neurological outcome.<sup>1</sup> Consistent, objective, evidence-based, and accurate neuroprognostication of patients is crucial to avoid inappropriate WLST or prolonged, invasive, and costly therapies that could perpetuate patient and family suffering when there is no realistic chance of an acceptable functional neurological recovery.

A growing body of evidence<sup>2,3</sup> and several guidelines exist<sup>1,4-9</sup> for assisting clinicians in assessment of neurological prognosis. Ideally, neuroprognostication should be undertaken after confounding factors have been excluded and sufficient time has elapsed. Guidelines outline recommendations for neurological examination, diagnostic imaging, neurophysiologic tests, and biomarker findings that predict a poor prognosis. Due to the risk of “false-positive” prediction of poor outcome and resultant “self-fulfilling prophecies,” a multimodal approach to neuroprognostication is recommended.<sup>1,4</sup> Canadian guidelines<sup>10</sup> for the care of the post-cardiac arrest patient are available, and Canadian guidelines for neuroprognostication postarrest have recently been published.<sup>9</sup>

Despite this large body of literature, guideline recommendations are based on relatively low-quality evidence, which likely contributes to variability of practices.<sup>11</sup> Potential areas of controversy include what constitutes a confounding factor, the minimum amount of time that is needed to definitively conclude that a patient's prognosis is poor, how best to approach multimodal prognostication, and what false-positive rate (FPR) is acceptable when determining prognosis. Furthermore, institutional protocols, perceptions of practitioners regarding accuracy of diagnostic modalities, and access to tests may influence neuroprognostication practices.

In view of this uncertainty, we conducted a cross-sectional survey of Canadian healthcare providers to investigate current practices and opinions regarding neuroprognostication in comatose post-cardiac arrest patients.

## Methods

This study was approved by the University of Calgary Conjoint Health Research Ethics Board. The survey was designed based on recent recommendations.<sup>12,13</sup> The survey was endorsed and distributed by the Canadian Critical Care Society (CCCS), the Canadian Cardiovascular Society (CCS), the Canadian Neurological Sciences Federation (CNSF), and through program contacts from the University of Calgary.

Our sampling frame consisted of intensivists, cardiologists, and neurologists who regularly care for adult ( $\geq 18$  years old) post-cardiac arrest patients. We specifically targeted physicians practicing in academic (with affiliated Royal College of

Physicians and Surgeons of Canada certified training programs) or nonacademic Canadian hospitals, to obtain a breadth of opinions and practices. Both English- and French-speaking physicians were surveyed.

Survey development was led by two investigators (CMB and JAK) based on a MEDLINE review of relevant literature. Feedback from other neurocritical care specialists (AHK and PC) was obtained. Domains that were considered important included: (1) demographics, experience, and confidence with postarrest neuroprognostication; (2) use of guidelines or institutional protocols; (3) timing of prognostic assessments; (4) confounders that may interfere with neuroprognostication; (5) interpretation and perceived utility of neurological examination findings; (6) availability, interpretation, and perceived utility of diagnostic tests; (7) multimodal neuroprognostication considerations; and (8) provider distress during neuroprognostication. For the survey, a poor neurological prognosis was defined as a cerebral performance category (CPC) of 3–5 (severe neurological disability, persistent vegetative state, and death).

Based on these domains, possible questions were generated (CMB), which were, in turn, reviewed by a panel of neurocritical care specialists (JAK, AHK, and PC). Redundant questions, or those considered irrelevant by unanimous agreement, were removed to achieve a manageable number. Formatting was completed by a panel of three individuals (CMB, MM, and JAK), with attention to strategic ordering of questions to avoid influencing responses. The survey was designed to ensure respondents could not return to previous questions to adjust their answers.

Pretesting of the survey was undertaken by a group of experts from centers across Canada, who reviewed questions to ensure adequate clarity, relevance, and consistency in interpretation of the questions.

Pilot testing was completed by intensivists, cardiologists, and neurologists from a single Canadian center (University of Calgary), who were asked to comment on flow, salience, clarity, and administrative ease of the questionnaire. Modifications were made accordingly.

The survey was then disseminated nationally. Purposive sampling was utilized as individuals were invited to participate by the CCCS, CCS, and CNSF. The CCCS sent the survey by email to physician members for participation, the CCS posted the survey to its member's board for participation, and the CNSF shared the survey for participation on their website for all members. In addition, the study team contacted physicians in each respective specialty at major academic institutions who were then asked to distribute the survey to others. Between two and three subsequent reminder emails were sent at approximately 2-week intervals in accordance with each professional association's survey policies.

The survey was anonymous, self-administered by respondents, voluntary, and completed online using REDCap (see online appendix for a copy of the survey).<sup>14</sup> The survey required

approximately 20 minutes to complete and was available in both English and French. No monetary or other incentive was offered for completion or participation.

Data were exported from REDCap into Excel.<sup>14</sup> Statistical analysis was performed (MM) using IBM SPSS Statistics for Windows, version 25.<sup>15</sup> Results were reported as numbers and percentages of individuals who answered each question completely. The data were analyzed using Fisher's exact test.

## Results

### Physician Demographics

The survey was distributed to 397 members of the CCCS, 1174 physicians from the CCS, and 1200 members of the CNSF. At least a portion of the survey was completed by 134 physicians. All surveys with responses to questions beyond the demographic section were included in the analysis.

There were responses from across the country, 91 (71%) of which were from Western Canada (British Columbia, Alberta, Saskatchewan, and Manitoba) followed by Ontario ( $n = 24$ , 19%), Quebec ( $n = 11$ , 9%), and Atlantic Canada ( $n = 2$ , 1.6%). There were no respondents from Northern territories. Respondents most often identified their specialty as critical care ( $n = 97$ , 72%), followed by neurology ( $n = 22$ , 16%), and cardiology ( $n = 15$ , 11%). Most respondents practice in academic centers ( $n = 109$ , 90%), with 500 or more beds ( $n = 85$ , 70%), that admit up to 100 postarrest patients per year ( $n = 62$ , 52%). There was a relatively equal distribution of early (0–10 years;  $n = 53$ , 42%), mid (11–20 years;  $n = 32$ , 25%), and late (>20 years;  $n = 43$ , 33%) career physicians. Most physicians ( $n = 89$ , 74%) prognosticated between 1 and 15 postarrest patients per year (Table 1, Supplement Table S1).

### Use of Guidelines or Institutional Protocols

The majority ( $n = 72$ , 54%) of respondents utilize the American Heart Association (AHA) guidelines<sup>4</sup> followed by European Resuscitation Council (ERC)/European Society of Intensive Care Medicine<sup>1</sup> ( $n = 39$ , 29%) and American Academy of Neurology (AAN)<sup>7</sup> ( $n = 39$ , 29%) guidelines. Of the physicians who utilize the AAN<sup>7</sup> guidelines published in 2006<sup>7</sup>, 92% ( $n = 36$ ) practice in academic centers. The majority of physicians who reported use the AAN<sup>7</sup> guidelines are from Western Canada ( $n = 36$ , 92%) and Quebec ( $n = 4$ , 10%). Of the total number of respondents from each discipline who participated in the survey, there was a total of 27 (69%) critical care physicians, 11 (28%) neurologists, and 1 (50%) neurocritical care physician who identified that they use the AAN<sup>7</sup> guidelines to guide postarrest management and neuroprognostication. Most physicians ( $n = 70$ , 63%) reported having no institutional protocols to guide postarrest neuroprognostication practices (Table 1).

When asked about targeted temperature management (TTM) for postarrest patients with a depressed level of consciousness, most physicians identified that they target eutherma ( $n = 57$ , 49%). There were 39 (33%) and 5 (4%) academic and 5 (4%) and 2 (2%) nonacademic respondents who target 34–36°C and 32–34°C, respectively ( $p = 0.24$ ). Of those physicians who specified a specific temperature target, the majority ( $n = 77$ , 66%) maintained this target for 24–48 hours. Only a small number ( $n = 5$ , 4%) of physicians do not target a specific temperature in any postarrest patient (Table 1).

### Timing of Neuroprognostication

The use of TTM had no significant effect on the time point where physicians were comfortable concluding that patients had a poor prognosis (Figure 1, Supplement Table S2). The number of definitive findings needed to conclude that the prognosis is poor affected the timing when physicians were comfortable and certain in decision-making. Over 50% preferred to wait beyond 5 and 8 days when only 1 or 0 definitive findings suggestive of a poor prognosis were present, respectively. When only one definitive finding suggested a poor prognosis post-rewarming if TTM was performed, 17% ( $n = 16$ ) of physicians expressed uncertainty as to when they conclude that the prognosis is poor. In contrast, when there were two or more definitive findings suggestive of a poor prognosis post-TTM rewarming, 61% ( $n = 57$ ) of physicians were comfortable determining a poor neurological prognosis between day 3 and 5. Additionally, when two or more definitive findings suggestive of a poor prognosis are present without the use of TTM, 55% ( $n = 51$ ) of physicians were comfortable determining a poor neurological prognosis between day 3 and 5. Only one (1%) physician expressed uncertainty as to when they could conclude a poor prognosis under these circumstances (Figure 1, Supplement Table S2).

The earliest time point physicians were comfortable concluding a patient has a poor prognosis with two or more definitive findings was less than 24 hours post-return of spontaneous circulation (ROSC) if no TTM was performed ( $n = 4$ , 4%). A small proportion ( $n = 6$ , 7%) of physicians identified that less than 24 hours postarrest is the earliest time points postarrest that they would be comfortable clinically determining death by neurological criteria (DNC) (Supplement Table S3).

### Confounders

The proportion of respondents who agreed on potential confounders is shown in Table 2. Over 60% of respondents agreed on the following major confounders to the neurological exam: ongoing infusions or impaired clearance of propofol, benzodiazepines, or opioids; clinically significant drug intoxication within 48 hours; core temperature <34°C; glucose <2.2 mmol/L; Na <120 and >160 mmol/L; severe hepatic dysfunction; and both convulsive and nonconvulsive seizures within 24 hours. With electroencephalography (EEG), over 60% agreed that ongoing infusions or impaired clearance of propofol or benzodiazepines, as well as clinically significant drug intoxications within 48 hours would confound interpretation. No potential confounder reached over 60% agreement for somatosensory evoked potentials (SSEPs).

Other potential confounders that were highlighted by physicians included cardiorespiratory instability, hypercapnia, hypoxemia, severe acidosis, cervical spine injury, additional concomitant cerebral pathology (e.g., subdural hemorrhage and hydrocephalus), neuromuscular blockade, and profound hypophosphatemia.

### Neurological Examination

Regarding the neurological exam, 85, 80, and 75% ( $n = 88$ , 82, and 77) of physicians identified bilaterally absent pupillary light reflexes (PLR), bilaterally absent corneal reflexes (CR), and status myoclonus (SM,  $\geq 30$  min of sustained, diffuse myoclonus) respectively, as useful in determining that a patient has a poor prognosis (Table 3, Supplement Table S4).

**Table 1:** Demographics of survey respondents

	N (% of total answered) <sup>‡</sup>	
<b>Specialty</b>		
Critical care	97 (72.4)	
Neurology	22 (16.4)	
Cardiology	15 (11.2)	
<b>Independent practice (yr)</b>		
0–10	53 (41.5)	
11–20	32 (25.0)	
>20	43 (33.6)	
<b>Province of practice</b>		
Western Canada	91(71.2)	
Ontario	24 (18.8)	
Quebec	11 (8.6)	
Atlantic Canada	2 (1.6)	
<b>Type of medical center</b>		
Academic	109 (90.1)	
Nonacademic	12 (9.9)	
<b>Post-cardiac arrests patients (#/center/year)</b>		
0	1 (0.8)	
1–50	26 (21.7)	
51–100	36 (30.0)	
>100	38 (31.7)	
Unsure	19 (15.8)	
<b>Post-arrest prognostications (#/physician/year)</b>		
0	7 (5.8)	
1–10	52 (43.0)	
10–25	53 (43.8)	
>25	9 (7.4)	
	Academic	Nonacademic
<b>Institutional neuroprognostication protocols</b>		
No	59 (59.0)	11 (91.7)
Yes	26 (26.0)	1 (8.3)
Unsure	15 (15.0)	0 (0)
<b>Guideline used</b>		
AHA	63 (57.8)	9 (75.0)
AAN	36 (33.0)	3 (25.0)
ERC	34 (31.2)	5 (41.7)
ANZCOR	6 (5.5%)	0 (0)
<b>Temperature targeted postarrest*</b>		
32–34°C	5 (4.8)	2 (16.7)
34–36°C	39 (37.1)	5 (41.7)
Euthermia (<37.5°C)	52 (49.5)	5 (41.7)
Fever avoidance (<38°C)	4 (3.8)	0 (0)
No specific target	5 (4.8)	0 (0)
<b>Duration above temperature target maintained</b>		
<24 hrs	6 (5.7)	0 (0)

(Continued)

**Table 1:** (Continued)

	N (% of total answered) <sup>‡</sup>	
24–48 hrs	67 (63.8)	10 (83.3)
48–72 hrs	24 (22.9)	1 (8.3)
Other <sup>†</sup>	2 (1.9)	1 (8.3)
NA – do not target specific temperature	6 (5.7)	0 (0)

<sup>‡</sup>Valid percentages; \*for those patients not following commands. <sup>†</sup>All respondents indicated until patient wakes or is discharged from intensive care unit; % – (valid) percentage; # – number; AAN – American Academy of Neurology; AHA – American Heart Association; ERC – European Resuscitation Council; ANZCOR – Australian and New Zealand Committee on Resuscitation; °C – degrees Celsius; hrs – hours; NA – not applicable; % academic versus nonacademic is reflective of valid % within each type of center.

Opinions regarding the timing of when exam findings could be used to predict a poor prognosis varied widely (Table 3, Supplement Table S5). A large proportion of respondents indicated that extensor ( $n = 87$ , 90%) or flexor ( $n = 77$ , 79%) posturing could be reliably used to predict a poor prognosis before 7 days postarrest. Only 40% ( $n = 39$ ) and 39% ( $n = 38$ ) of physicians indicated that the bilateral absence of PLR and CR, respectively, could be used to predict a poor prognosis on postarrest day 3 and beyond, with the majority of other respondents indicating these findings could be used earlier in a patient's course to conclude a poor prognosis.

#### Test Availability, Interpretation, and Perceived Utility

Twenty percent ( $n = 19$ ) of respondents indicated that a FPR of <5% for a diagnostic test is necessary for it to be considered definitive in neuroprognostication. Of these physicians, 79% ( $n = 15$ ) practice in academic centers and 32% ( $n = 6$ ,  $p = 0.045$ ) have been practicing less than 5 years as an independent licensed physician. Thirty-two percent ( $n = 31$ ) of physicians indicated that an FPR of <2.5% was preferable. Of these physicians, 87% ( $n = 27$ ) practice in academic centers and 13% ( $n = 4$ ,  $p = 0.045$ ) have been practicing less than 5 years as an independent licensed physician. Of the physicians who chose an FPR of <1% (49%,  $n = 47$ ), 92% ( $n = 43$ ) practice in academic centers and 23% ( $n = 11$ ,  $p = 0.045$ ) have been practicing less than 5 years as an independent licensed physician.

Neuroprognostication test accessibility, perceived utility, and the time point at which specific findings can be used to conclude a poor prognosis are outlined in Table 4. Computed tomography (CT), magnetic resonance imaging (MRI), and routine (not continuous) electroencephalography (EEG) are easily available to 98, 87, and 82% ( $n = 98$ , 87, and 82) of physicians, respectively. SSEPs are available to 73% ( $n = 73$ ) of physicians, but logistical challenges must often be navigated when trying to organize this test. The majority of physicians indicated that serum biomarkers [neuron-specific enolase (NSE), protein S-100B, creatinine kinase BB, tau, neurofilament light chain, glial fibrillary acidic protein (GFAP), and ubiquitin C terminal hydrolase-L1 (UCH-L1)] are not available at their centers (Supplement Table S6).

SSEP ( $n = 76$ , 76%), MRI ( $n = 75$ , 75%), CT ( $n = 62$ , 62%), and EEG ( $n = 61$ , 61%) were considered the most useful tests for neuroprognostication. Despite this, a variable number of physicians indicated certain findings on MRI, CT, and EEG (that are proven in the literature to predict a poor prognosis) were not reliable (Table 4, Supplement Table S7). Most indicated that they were unsure of the utility of serum

biomarkers. Opinions regarding the timing by which test findings could be used to predict a poor prognosis varied widely (Table 4, Supplement Table S8).


#### Multimodal Neuroprognostication Considerations

Eighty-nine percent ( $n = 85$ ) of respondents agreed if there are no definitive findings on the neurological exam, electrophysiologic tests, neuroimaging, or biomarkers, the prognosis is unclear. Most ( $n = 76$ , 79%) believed that  $\geq 2$  definitive findings on either the neurological exam, neurophysiologic tests, neuroimaging, and/or biomarkers is required to conclude that a patient has a poor prognosis (CPC 3–5) with reasonable certainty (FPR <5%). There was no consensus regarding whether a single definitive finding could be used to conclude a poor prognosis with adequate certainty ( $n = 25$ , 26% agreed,  $n = 40$ , 42% neutral, and  $n = 31$ , 32% disagreed). Most respondents ( $n = 83$ , 87%) agreed that when utilizing  $\geq 2$  definitive findings to predict a poor prognosis (CPC 3–5), these should be from different categories (Figure 2).

In addition to the medical information obtained through multimodal neuroprognostication, respondents also indicated several other factors that should be taken into consideration when discussing goals of care. These included patient and family values, including religious and cultural beliefs, and expressed wishes such as those documented in advanced directives, the patient's age, preexisting conditions, baseline functional status, the level of disability/length of rehabilitation that the patient and/or family would be willing to accept and donation considerations (i.e., donation after death determination by circulatory criteria) as appropriate.

#### Provider Confidence and Distress

Approximately 57% ( $n = 64$ ) of physicians indicated feeling confident with accurately identifying patients with good (CPC 1–2) versus poor (CPC 3–5) outcomes at day 3–5 postarrest. (Supplement Figure S1a). However, 70% ( $n = 64$ ) of physicians indicated some level of distress (mild  $n = 39$ , 42%, moderate  $n = 23$ , 25%, and severe  $n = 2$ , 2%) when determining a patient's neurological prognosis (Supplement Figure S1b). Of the physicians who expressed mild and moderate distress, the majority were critical care physicians (80 and 58%, respectively) and for those who expressed severe distress, the responses were equally distributed between cardiologists (50%) and neurologists (50%). In addition, 51% ( $n = 47$ ) of physicians frequently requested a second opinion from a colleague or external expert (neurology,  $n = 43$ ; critical care/ICU,  $n = 39$ ; neurocritical care,  $n = 32$ ).



**Figure 1:** Percentage\* of respondents indicating the earliest time point they are comfortable concluding a comatose patient with an unconfounded assessment has a poor neurologic prognosis (CPC 3–5) based on clinical scenarios. **A:** Earliest time point post-TTM<sup>‡</sup> rewarming to normothermia that physicians are comfortable concluding a poor neurological prognosis (CPC 3–5) in unconfounded comatose\*\* patients. **B:** Earliest time point post-ROSC when no TTM performed that physicians are comfortable concluding a poor neurological prognosis (CPC 3–5) in unconfounded comatose\*\* patients. \*Reported as valid percentages; † TTM – Targeted Temperature Management 32–36°C; \*\* Comatose defined as GCS ≤ 8; Confounders – see Table 2; Definitive findings – Exam: bilaterally absent pupillary light reflexes, bilaterally absent corneal reflexes, absent oculocephalic reflex, bilaterally absent vestibulo-ocular reflex, bilaterally absent gag reflex, absent cough reflex, lack of eye opening to painful stimuli, lack of purposeful motor response / EEG: status myoclonus, isoelectric background (<2 uV), suppressed background (<10 uV), highly epileptiform BS, non-epileptiform BS, GPDs on suppressed background, electrographic seizures, absent reactivity / SSEP: bilaterally absent N20 potentials / CT: subjective loss of gray-white, GM/WM <1.15 / MRI: extensive restricted diffusion of deep gray matter, extensive restricted diffusion of cerebral cortex, extensive restricted diffusion of cortex and deep gray matter / Serum Biomarkers: NSE (>33 ug/L, >60 ug/L), Protein S-100B, Creatine Kinase BB, Tau, Neurofilament Light Chain, GFAP, UCH-L1.

**Table 2:** Number (percentage)<sup>†</sup> of respondents identifying major confounders of the neurologic examination, electroencephalography, and somatosensory evoked potentials

Potential confounder	N (%) <sup>†</sup> indicating major confounder of		
	Neuro exam	EEG	SSEP
Propofol*	95 (70.9)	93 (69.4)	23 (17.2)
Benzodiazepines*	102 (76.1)	101 (75.4)	30 (22.4)
Opioids*	99 (73.9)	59 (44.0)	20 (14.9)
Clinically significant drug intoxications within 48 hours	104 (77.6)	92 (68.7)	35 (26.1)
Core temperature			
<34°C	94 (70.1)	71 (53.0)	47(35.1)
>38°C	36 (26.9)	20 (14.9)	12 (9.0)
Glucose			
<2.2 mmol/L	103 (76.9)	68 (50.7)	32 (23.9)
>22 mmol/L	46 (34.3)	20 (14.9)	6 (4.5)
Sodium			
<120 mmol/L	97 (72.4)	54 (40.3)	20 (14.9)
>160 mmol/L	85 (63.4)	39 (29.1)	16 (11.9)
Stage 3 acute kidney injury <sup>†</sup>	53 (39.6)	33 (24.6)	9 (6.7)
Hepatic dysfunction <sup>††</sup>	96 (71.6)	66 (49.3)	14 (10.4)
Convulsive seizure within 24 hours	100 (74.6)	80 (59.7)	46 (34.3)
Nonconvulsive seizures within 24 hours	98 (73.1)	78 (58.2)	42 (31.3)
Concern for critical illness neuropathy/myopathy	78 (58.2)	14 (10.4)	29 (21.6)

<sup>†</sup>Valid percentages; \* defined as ongoing infusion or impaired clearance with infusion discontinued within 48 hours; <sup>†</sup> defined as Cr<sub>2</sub>≥3 times the upper limit of normal; <sup>††</sup> defined as evidence of synthetic dysfunction.

## Discussion

Our findings demonstrate significant variability exists across Canada in neuroprognostication practices following cardiac arrest that are often inconsistent with recommendations from current guidelines.<sup>1,4,5,7-10</sup> While previous post-cardiac arrest prognostication surveys have been published,<sup>11,16-20</sup> our study assesses more in-depth neuroprognostication considerations, including multimodal aspects, and describes opinions from academic and nonacademic intensivists, neurologists, and cardiologists from across Canada.

We identified that approximately 30% of respondents utilize the AAN guidelines. These were published in 2006 and have yet to be updated with contemporary evidence.<sup>2,3</sup> This finding suggests that almost a third of Canadian physicians performing neuroprognostication may be doing so based on outdated guidance. Over 60% of facilities where respondents are employed do not have institutional protocols for postarrest care or neuroprognostication. Literature suggests that standardized critical care management protocols improve patient outcomes, streamline care, and facilitate continuing medical education.<sup>21-24</sup> Protocols may influence consistency across providers regarding timing of prognostication, exclusion of confounders, pertinent examination findings, useful diagnostic tests and relevant findings, as well as multimodal neuroprognostication considerations. In addition, protocols may

help improve relative lack of confidence and variable levels of distress that 43 and 70% of physicians reported, respectively.

Timing of neuroprognostication is discussed at length throughout the literature, and AHA,<sup>4</sup> ERC,<sup>1</sup> and AAN<sup>7</sup> guidelines recommend deferring definitive neuroprognostication for at least 72 hours post-ROSC or return of normothermia when TTM is utilized. Despite this, our results show that the use of TTM had no statistically significant impact on the timing of neuroprognostication. A small proportion of physicians expressed comfort determining a definitive prognosis for patients 24 hours or less postarrest. Utilizing suboptimal time points during the process of neuroprognostication in this patient population is a modifiable factor that, if addressed, may improve accuracy.

A small proportion of physicians (7%) indicated comfort declaring DNC 24 hours or less post-ROSC. Many guidelines<sup>25,26</sup> caution against clinically declaring DNC within 24–48 hours postarrest, while others do not.<sup>7</sup> The recently published Canadian guidelines<sup>27</sup> suggest delaying the clinical assessment for DNC for at least 48 hours from ROSC, unless there is imaging evidence consistent with devastating brain injury.<sup>27</sup> If there is radiographic evidence of devastating brain injury, the new guidelines suggest earlier determination of DNC is appropriate. In these circumstances where earlier DNC is suspected, it is important to consider that confounders may be present. Our survey results show that 57% of physicians currently are comfortable declaring death within 48 hours from an arrest. While our survey did not specify neuroimaging findings in the question, this suggests that significant knowledge translation may be required to ensure practices are aligned with updated guidelines.

Guidelines stress the importance of ensuring potential confounders are excluded during the process of neuroprognostication but do not provide more specific recommendations. To our knowledge, this survey is the first to ask detailed questions regarding possible confounders. The median threshold to define consensus based on Delphi criteria<sup>28,29</sup> is ≥75%. Our results highlight the lack of consensus surrounding what factors should be considered confounders of not only the neurological exam, but also EEG and SSEPs. Further research and consensus building efforts in this area are warranted.

Similar to other surveys<sup>11,16-20</sup> Canadian respondents placed high utility on several elements of the neurological examination. Over 90% indicated that bilaterally absent PLR or CR had some level of utility (53 and 44% very useful, 32 and 36% useful, 11 and 12% somewhat useful for PLR and CR, respectively) for neuroprognostication. While this is congruent with guidelines, at least 30 and 40% indicated that bilaterally absent PLR and CR, respectively, could be used to accurately predict a poor prognosis earlier than guideline recommendations of 72 hours. Respondents also indicated utility of other elements of the neurological exam that have not been validated as predictors. Specifically, over 80% of respondents indicated some utility (22% very useful, 28% useful, and 32% somewhat useful) of a lack of purposeful motor response when evaluated in insolation and more than 70% indicated this could be used within 5 days post-ROSC. This is despite evidence suggesting an unacceptably high FPR for both extensor and flexor posturing.<sup>21</sup> The perceived differences in utility between SM and other forms of myoclonus suggests increasing awareness by Canadian physicians of the varying clinical implications of different types of postarrest myoclonus.<sup>30,31</sup>

Our results highlight important discrepancies in access to diagnostic tests for neuroprognostication across Canada. Over 10, 15, and 75% of physicians indicated a lack of access or logistical

**Table 3:** Perceived utility and earliest time post-ROSC and return of normothermia that physical exam findings can be used to predict a poor neurologic prognosis (CPC 3–5)

Physical exam findings	Utility N (%) <sup>†</sup>		Earliest time post-ROSC/normothermia finding can be used to indicate a poor prognosis (CPC 3–5) N (%) <sup>††</sup>				
	Useful	Limited utility	<24 hr	24–72 hr	73–120 hr	121–168 hr	>168 hr
Bilaterally absent pupillary light reflexes	99 (96.1)	4 (3.9)	6 (6.2)	49 (50.6)	38 (39.2)	1 (1.0)	0 (0)
Bilaterally absent corneal reflexes	94 (91.3)	8 (7.8)	4 (4.1)	45 (46.4)	36 (37.2)	2 (2.1)	0 (0)
Absent oculocephalic reflex	83 (80.7)	19 (18.4)					
Bilaterally absent vestibulo-ocular reflex	87 (84.4)	14 (13.6)					
Bilaterally absent gag reflex	64 (62.2)	39 (37.9)					
Absent cough reflex	71 (68.9)	31 (30.1)					
Lack of eye opening to painful stimuli	61 (59.2)	42 (40.8)					
Lack of purposeful motor response	85 (82.5)	18 (17.5)					
GCS <sub>m</sub> ≤ 2			2 (2.1)	32 (32.9)	48 (49.5)	5 (5.1)	3 (3.1)
GCS <sub>m</sub> ≤ 3			2 (2.1)	26 (26.8)	43 (44.3)	6 (6.2)	3 (3.1)
Status myoclonus*	91 (88.4)	10 (9.7)	22 (22.7)	41 (42.3)	21 (21.6)	5 (5.2)	0 (0)
Other myoclonus	59 (57.3)	37 (35.9)					

<sup>†</sup>Valid percentages reported – missing percentages are of those who indicated “unsure” to the question of utility; <sup>††</sup> valid percentages reported – missing percentages are those who either indicated the finding was “not reliably predictive of a poor prognosis” or “unsure” to the question regarding timing; \* defined as ≥30 min sustained, diffuse myoclonus.

challenges when arranging MRI, EEG, and SSEPs, respectively. Considering multimodal prognostication is recommended in guidelines, this highlights major access inequities within the Canadian health system that require attention. In particular, access to SSEPs should be increased.

Nearly 60% of individuals indicated similar concerns for access to continuous EEG. The recently published TELSTAR trial<sup>32</sup> suggests no improvement in outcomes when rhythmic and periodic EEG activity is suppressed with antiseizure medications. The characteristics of patients enrolled (nearly 60% with myoclonus and 30% lacking N20 potentials); only 56% success in achieving the treatment goal (48 hours of suppressed activity); and a high WLST rate (including within the first 24 hours) limit the external validity of this trial. Other studies suggest aggressive treatment of carefully selected individuals with rhythmic and periodic EEG activity or electrographic seizures may have benefits.<sup>33</sup> Therefore, access to continuous EEG for select postarrest patients who may benefit from aggressive treatment is needed. While not all institutions will be able to implement this, there should be clear pathways in place that allows for triaging and transferring of patients who may benefit from aggressive treatment to centers with continuous EEG capabilities.

When assuming all tests are available, Canadian physicians placed similar importance on EEG and neuroimaging tests despite established and stronger evidence for SSEPs.<sup>2</sup> Most respondents indicated uncertainty regarding the utility of biomarkers that matches the evolving literature in this area.<sup>9,34</sup>

Despite evidence and guidelines specifying time points at which certain test findings accurately indicate a poor prognosis, several physicians utilize them at time points of lower yield or may utilize findings that are not yet fully proven to definitively suggest a poor prognosis. Much of the EEG literature suggests a high FPR for certain patterns detected less than 24 hours post-ROSC (e.g., nonsynchronous burst suppression), likely related to acute confounders (such as sedation, metabolic derangements, or hypothermia) that may influence the EEG during this time. Nevertheless, approximately 10% of respondents indicated that

such EEG patterns detected less than 24 hours post-ROSC definitively suggested a poor prognosis. Only one-third of individuals responded that EEG reactivity is not a reliable predictor of prognosis. Evolving literature that suggests more objective means of both testing and measuring EEG reactivity need to be established.<sup>35–47</sup>

Another important consideration in diagnostic test interpretation is that of ensuring tests are interpreted by individuals not only with expertise within the modality but also with content expertise in integrating various findings and multimodal neuroprognostication. For example, while existing literature does not identify a critical threshold for volume of restricted diffusion on MRI to conclude a poor prognosis, no standardized reporting format has been suggested in the literature to guide reporting of neuroimaging for these patients. Thus, similar wording may be used to describe scans with a large or small burden of HIBI. It would therefore be advisable, when possible, for physicians, performing neuroprognostication, to review all test results, in addition to the reports themselves. The survey did not allow us to infer practitioner’s comfort at interpreting tests independently and their relative reliance on written diagnostic reports within this context. Further assessment of physician comfort with interpretation of prognosticating tests in this clinical context would be prudent.

The majority of physicians indicated a FPR of <1–2.5% was preferable in order to rely on diagnostic tests to predict a poor prognosis. A recent international survey that involved few Canadians and found medical providers preferred a FPR of <0.1% for recommending WLST.<sup>18</sup> Our survey did not allow respondents to choose a percentage lower than 1%. The FPRs of all individual post-cardiac arrest diagnostic tests have confidence intervals that exceed these limits, therefore highlighting the importance of multimodal approaches. Most respondents agreed that ≥2 congruent predictive findings are required to definitively conclude that a patient has a poor neurological prognosis during the first week postarrest, and that these two findings should be from different categories (neurological exam,




**Table 4:** Accessibility, perceived utility, and earliest time post-ROSC/normothermia ancillary tests can be used to predict a poor neurological prognosis

Ancillary test and findings	Availability <i>N</i> (%) <sup>†</sup>			Utility <i>N</i> (%) <sup>††</sup>		Earliest time post-ROSC/normothermia finding can be used in isolation to indicate a poor prognosis (CPC 3–5) <i>N</i> (%) <sup>†††</sup>				
	Not available	Available but logistical challenges	Available and accessible	Useful	Limited utility	<24 hr	24–72 hr	73–120 hr	121–168 hr	>168 hr
EEG – spot	2 (2.0)	16 (16.0)	82 (82.0)	94 (94.0)	6 (6.0)					
EEG – continuous	23 (23.0)	36 (36.0)	40 (40.0)	86 (86.0)	9 (9.0)					
Isoelectric background (<2 uV)						13(13.4)	32(33.0)	26(26.8)	14(14.4)	5(5.2)
Suppressed background (<10 uV)						5(5.2)	23(23.7)	20(20.6)	16(16.5)	1(1.0)
Highly epileptiform BS						12(12.4)	27(27.8)	16(16.5)	12(12.4)	1(1.0)
Non-epileptiform BS						8(8.2)	28(28.96)	16(16.5)	9(9.3)	0(0)
GPDs on suppressed background						8(8.2)	20(20.6)	13(13.4)	14(14.5)	1(1.0)
Electrographic seizures						8(8.2)	14(14.5)	9(9.3)	12(12.3)	2(2.1)
Absent reactivity						10(10.3)	26(26.8)	17(17.5)	11(11.3)	1(1.0)
SSEP	25 (25.0)	54 (54.0)	19 (19.0)	90 (90.0)	3 (3.0)					
Bilaterally absent N20 potentials						8(8.23)	42(43.3)	27(27.8)	9(9.3)	0(0)
CT	2 (2.0)	0 (0)	98 (98.0)	93 (93.0)	6 (6.0)					
Subjective loss of gray-white differentiation						10(10.3)	34(35.1)	11(11.3)	5(5.1)	1(1.0)
GM/WM <1.15						10(10.3)	19(19.6)	13(13.4)	17(17.5)	0(0)
MRI	2 (2.0)	11 (11.0)	87 (87.0)	95 (95.0)	4 (4.0)					
Extensive restricted diffusion of deep gray matter						4(4.1)	28(28.8)	21(21.6)	10(10.3)	1(1.0)
Extensive restricted diffusion of cerebral cortex only						2(2.1)	20(20.6)	23(23.7)	10(10.3)	0(0)
Extensive restricted diffusion of cortex and deep gray matter						11(11.3)	28(28.9)	20(20.6)	8(8.2)	0(0)
NSE	66 (66.0)	17 (17.0)	7 (7.0)	36 (36.0)	8 (8.0)					
>33 ug/L						1(1.0)	7(7.2)	8(8.2)	28(28.9)	0(0)
>60 ug/L						0(0)	10(10.4)	0(0)	27(27.8)	0(0)
Protein S-100B	72 (72.0)	10 (10.0)	5 (5.0)	22 (22.0)	13(13.0)					
Creatinine kinase BB	54 (54.0)	12 (12.0)	20 (20.0)	12 (12.0)	20(20.0)					
Tau	67 (67.0)	16 (16.0)	1 (1.0)	9 (9.0)	17(17.0)					
Neurofilament light chain	66 (66.0)	18 (18.0)	0 (0)	15 (15.0)	12(12.0)					
GFAP	68 (68.0)	13 (13.0)	0 (0)	9 (9.0)	13(13.0)					
UCH-L1	71 (71.0)	10 (10.0)	0 (0)	7 (7.0)	15(15.0)					

<sup>†</sup>valid percentages <sup>††</sup> valid percentages – missing percentages are of those who indicated “unsure” to the question of utility; <sup>†††</sup> valid percentages – missing percentages are those who either indicated the finding was “not reliably predictive of a poor prognosis” or “unsure” to the question regarding timing; hr – hours; EEG – electroencephalography; uV – microvolts; BS – burst suppression; GPD – generalized periodic discharge; SSEP – somatosensory evoked potentials; CT – computer tomography; GM – gray matter; WM – white matter; MRI – magnetic resonance imaging; NSE – neuron specific enolase; ug/L – micrograms per liter; GFAP – glial fibrillary acidic protein; UCH-L1 – ubiquitin C terminal hydrolase-L1.

neuroimaging, EEG, SSEP, and/or biomarkers). Over 50% of respondents commonly request a second opinion. Clinicians practicing in centers with access to expertise in neuroprognostication and neurocritical care may predict functional outcomes more accurately and help alleviate provider reported distress.<sup>48</sup> In addition to medical information obtained through multimodal neuroprognostication, one of the factors that physicians indicated should be taken into consideration when discussing goals of care were donation after cardiac death (DCD). It is very important to note that one of the key concepts of DCD is that goals of care should not be influenced by DCD availability.<sup>49,50</sup>

This survey was designed with careful attention to recommended methodology and comprises a large representative cohort of Canadian physicians involved in neuroprognostication of postarrest patients. The release of the TTM2<sup>51</sup> trial results coincided closely with the circulation of our postarrest survey. Therefore,<sup>50</sup> the impact of the trial on physician practice is likely not reflected in the collected responses. This survey was distributed while Canadian guidelines for post-cardiac arrest neuroprognostication were in development. It is possible that some respondents were part of the guideline working group, and this may have impacted the survey responses. Survey validity is



**Figure 2:** Multimodal approach to neuroprognostication. **A:** If no definitive findings from the neurological exam, electrophysiologic tests, neuroimaging, or biomarkers are present, the prognosis is unclear. **B:** 1 definitive finding on either neurological exam, electrophysiologic tests, neuroimaging, or biomarkers indicates a poor prognosis (CPC 3–5) with adequate certainty (FPR <5%). **C:**  $\geq 2$  definitive findings on either neurological exam, electrophysiologic tests, neuroimaging, and/or biomarkers are required to conclude a patient has a poor prognosis (CPC 3–5) with adequate certainty (FPR <5%). **D:** Ideally, when using  $\geq 2$  definitive findings to predict a poor prognosis (CPC 3–5), these should be from different testing categories (i.e., neuroimaging and exam or neuroimaging and electrophysiologic tests, etc.). **E:** When  $\geq 2$  definitive findings are present, it is not necessary to obtain additional tests.

directly correlated with response rate and completion of the survey. Our sampling frame was selected specifically to target critical care physicians, neurologists, and cardiologists who routinely care for adult postarrest patients; however, we did not capture opinions from other relevant team members including nurse practitioners or medical trainees. In addition, the overall response rate was low, as with most surveys.<sup>13</sup> However, this response rate may be an underestimate since many of the physicians the survey was distributed to do not regularly care for postarrest patients. The length and complexity of the questionnaire may have influenced the completion rate. Despite efforts to balance survey completion with capturing sufficient information to understand practices, only 69% who initiated the survey completed it.

## Conclusions

Significant variability exists in post-cardiac arrest neuroprognostication practices among Canadian physicians. Practices that are

inconsistent with current guidelines are relatively common. Standardized neuroprognostication protocols based on best evidence regarding optimal timing of assessments, exclusion of confounding factors, use of the most pertinent findings of neurological examination, use of additional diagnostic tests, and implementation of multimodal considerations may improve consistency and accuracy. Access to evidence-based tests and second opinions from experts in this field are important considerations to address current inequities within the Canadian healthcare system and ensure that all postarrest patients undergo individualized, evidence-based neuroprognostication. Further research is warranted to continue to advance this field and incorporate best evidence into practice.

**Supplementary material.** The supplementary material for this article can be found at <https://doi.org/10.1017/cjn.2023.261>.

**Acknowledgments.** We acknowledge and thank the Canadian Cardiovascular Society, the Canadian Critical Care Society, the Canadian Neurological Sciences Federation, Dr Dan Zuege (Department Head – Department of Critical Care

Medicine – Calgary, Canada), Dr Lara Cooke (Section Chief – Department of Clinical Neurosciences, Division of Neurology – Calgary, Canada), and Dr Carlos Morillo (Section Chief – Department of Cardiac Sciences, Division of Cardiology – Calgary, Canada) for endorsing and distributing our survey.

### Funding.

- Caralyn M. Bencsik has no disclosures or funding to declare.
- Dr Andreas H. Kramer was the co-chair of the Canadian Cardiovascular Society Position Statement for Neuroprognostication of the post-cardiac arrest patient. He is the Medical Director of the Southern Alberta Organ & Tissue Donation Program.
- Dr Philippe Couillard has no disclosures or funding to declare.
- Maarit MacKay has no disclosures or funding to declare.
- Dr Julie A. Kromm was the lead for the electrophysiology section of the Canadian Cardiovascular Society Position Statement for Neuroprognostication of the post-cardiac arrest patient.

### Competing interests.

- Caralyn M. Bencsik has no conflict of interest to declare.
- Dr Andreas H. Kramer has no conflict of interest to declare.
- Dr Philippe Couillard has no conflict of interest to declare.
- Maarit MacKay has no conflict of interest to declare.
- Dr Julie A. Kromm has no conflict of interest to declare.

### Statement of authorship.

- Caralyn Bencsik contributed to the conception and design of the study, acquisition, and interpretation of data, drafting, and critically revising the manuscript for intellectual content and approved the final version of the manuscript.
- Andreas Kramer contributed to the conception and design of the study, acquisition, and interpretation of data, drafting, and critically revising the manuscript for intellectual content and approved the final version of the manuscript.
- Philippe Couillard contributed to the conception and design of the study, acquisition, and interpretation of data, drafting, and critically revising the manuscript for intellectual content and approved the final version of the manuscript.
- Maarit Mackay contributed to the acquisition, analysis, and interpretation of the data, and critically revising the manuscript for intellectual content and approved the final version of the manuscript.
- Julie Kromm contributed to the conception and design of the study, acquisition, and interpretation of data, drafting, and critically revising the manuscript for intellectual content and approved the final version of the manuscript.

### References

1. Nolan JP, Sandroni C, Böttiger BW, et al. European Resuscitation Council and European Society of Intensive Care Medicine guidelines 2021: post-resuscitation care. *Intensive Care Med.* 2021;47:369–421. DOI: [10.1007/s00134-021-06368-4](https://doi.org/10.1007/s00134-021-06368-4).
2. Sandroni C, D'Arrigo S, Cacciola S, et al. Prediction of poor neurological outcome in comatose survivors of cardiac arrest: a systematic review. *Intensive Care Med.* 2020;46:1803–51. DOI: [10.1007/s00134-020-06198-w](https://doi.org/10.1007/s00134-020-06198-w).
3. Sandroni C, D'Arrigo S, Cacciola S, et al. Prediction of good neurological outcome in comatose survivors of cardiac arrest: a systematic review. *Intensive Care Med.* 2022;48:389–413. DOI: [10.1007/s00134-022-06618-z](https://doi.org/10.1007/s00134-022-06618-z).
4. Geocadin RG, Callaway CW, Fink EL, et al. Standards for studies of neurological prognostication in comatose survivors of cardiac arrest: a scientific statement from the American Heart Association. *Circulation.* 2019;140:E517–E542. DOI: [10.1161/CIR.0000000000000702](https://doi.org/10.1161/CIR.0000000000000702).
5. ANZCOR. ANZCOR Guideline 11.7 – Post-resuscitation therapy in adult advanced life support; 2016: 1–17. <https://resus.org.au/the-arc-guidelines/>; accessed January 8, 2023.
6. Taccone FS, Baar I, De Deyne C, et al. Neuroprognostication after adult cardiac arrest treated with targeted temperature management: task force for Belgian recommendations. *Acta Neurol Belg.* 2017;117:3–15. DOI: [10.1007/s13760-017-0755-1](https://doi.org/10.1007/s13760-017-0755-1).
7. Wijdicks EFM, Hijdra A, Young GB, Bassetti CL, Wiebe S. Practice parameter: prediction of outcome in comatose survivors after cardiopulmonary resuscitation (an evidence-based review); 2006. [www.neurology.org](http://www.neurology.org).
8. Perkins GD, Graesner JT, Semeraro F, et al. European Resuscitation Council guidelines 2021: executive summary. *Resuscitation.* 2021;161:1–60. DOI: [10.1016/j.resuscitation.2021.02.003](https://doi.org/10.1016/j.resuscitation.2021.02.003).
9. Fordyce CB, Kramer AH, Ainsworth C, et al. Neuroprognostication in the post cardiac arrest patient: a Canadian Cardiovascular Society Position Statement. *Can J Cardiol.* 2023;39:366–80. DOI: [10.1016/j.cjca.2022.12.014](https://doi.org/10.1016/j.cjca.2022.12.014).
10. Wong GC, van Diepen S, Ainsworth C, et al. Canadian Cardiovascular Society/Canadian Cardiovascular Critical Care Society/Canadian Association of Interventional Cardiology Position Statement on the optimal care of the postarrest patient. *Can J Cardiol.* 2017;33:1–16. DOI: [10.1016/j.cjca.2016.10.021](https://doi.org/10.1016/j.cjca.2016.10.021).
11. Bray JE, Cartledge S, Finn J, et al. The current temperature: a survey of post-resuscitation care across Australian and New Zealand intensive care units. *Resusc Plus.* 2020;1-2:100002. DOI: [10.1016/j.resplu.2020.100002](https://doi.org/10.1016/j.resplu.2020.100002).
12. Burns KEA, Kho ME. How to assess a survey report: a guide for readers and peer reviewers. *CMAJ.* 2015;187:E198–E205. DOI: [10.1503/cmaj.140545](https://doi.org/10.1503/cmaj.140545).
13. Burns KEA, Duffett M, Kho ME, et al. A guide for the design and conduct of self-administered surveys of clinicians. *CMAJ Can Med Assoc J.* 2008;179:245–52. DOI: [10.1503/cmaj.080372](https://doi.org/10.1503/cmaj.080372).
14. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform.* 2009;42:377–81. DOI: [10.1016/j.jbi.2008.08.010](https://doi.org/10.1016/j.jbi.2008.08.010).
15. IBM Corp. IBM SPSS statistics for Windows, 2017.
16. Zhou SE, Barden MM, Gilmore EJ, et al. Postcardiac arrest neuroprognostication practices: a survey of Brazilian physicians. *Crit Care Explor.* 2021;3:e0321. DOI: [10.1097/ccc.0000000000000321](https://doi.org/10.1097/ccc.0000000000000321).
17. Friberg H, Cronberg T, Dünser MW, Duranteau J, Horn J, Oddo M. Survey on current practices for neurological prognostication after cardiac arrest. *Resuscitation.* 2015;90:158–62. DOI: [10.1016/j.resuscitation.2015.01.018](https://doi.org/10.1016/j.resuscitation.2015.01.018).
18. Steinberg A, Callaway CW, Arnold RM, et al. Prognostication after cardiac arrest: results of an international, multi-professional survey. *Resuscitation.* 2019;138:190–7. DOI: [10.1016/j.resuscitation.2019.03.016](https://doi.org/10.1016/j.resuscitation.2019.03.016).
19. Maciel CB, Barden MM, Youn TS, Dhakar MB, Greer DM. Neuroprognostication practices in postcardiac arrest patients: an international survey of critical care providers. *Crit Care Med.* 2020;48:E107–E114. DOI: [10.1097/CCM.00000000000004107](https://doi.org/10.1097/CCM.00000000000004107).
20. Lanfang D, Zheng K, Feng L, et al. The first national survey on practices of neurological prognostication after cardiac arrest in China, still a lot to do. *Int J Clin Pract.* 2020; 74: e13759. DOI: [10.22541/au.159466941.15741033](https://doi.org/10.22541/au.159466941.15741033).
21. Lellouche F, Mancebo J, Jolliet P, et al. A multicenter randomized trial of computer-driven protocolized weaning from mechanical ventilation. *Am J Respir Crit Care Med.* 2006;174:894–900. DOI: [10.1164/rccm.200511-1780OC](https://doi.org/10.1164/rccm.200511-1780OC).
22. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. *N Engl J Med.* 2000;342:1471–7. DOI: [10.1056/NEJM200005183422002](https://doi.org/10.1056/NEJM200005183422002).
23. English SW, Turgeon AF, Owen E, Doucette S, Pagliarello G, McIntyre L. Protocol management of severe traumatic brain injury in intensive care units: a systematic review. *Neurocrit Care.* 2013;18:131–42. DOI: [10.1007/s12028-012-9748-3](https://doi.org/10.1007/s12028-012-9748-3).
24. McCredie VA, Alali AS, Scales DC, Rubenfeld GD, Cuthbertson BH, Nathens AB. Impact of ICU structure and processes of care on outcomes after severe traumatic brain injury: a multicenter cohort study. *Crit Care Med.* 2018;46:1139–49. DOI: [10.1097/CCM.00000000000003149](https://doi.org/10.1097/CCM.00000000000003149).

25. Greer DM, Shemie SD, Lewis A, et al. Determination of brain death/death by neurologic criteria: the world brain death project. *JAMA*. 2020;324:1078–97. DOI: [10.1001/jama.2020.11586](https://doi.org/10.1001/jama.2020.11586).
26. Shemie SD, Doig C, Dickens B, et al. Severe brain injury to neurological determination of death: Canadian forum recommendations. *CMAJ*. 2006;174:S1–13. DOI: [10.1503/cmaj.045142](https://doi.org/10.1503/cmaj.045142).
27. Shemie SD, Wilson LC, Hornby L, et al. A brain-based definition of death and criteria for its determination after arrest of circulation or neurologic function in Canada: a 2023 clinical practice guideline. *Can J Anesth*. 2023;70:483–557. DOI: [10.1007/s12630](https://doi.org/10.1007/s12630).
28. Diamond IR, Grant RC, Feldman BM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. *J Clin Epidemiol*. 2014;67:401–9. DOI: [10.1016/j.jclinepi.2013.12.002](https://doi.org/10.1016/j.jclinepi.2013.12.002).
29. Jaworska N, Makuk K, Krewulak KD, et al. A national modified Delphi consensus process to prioritize experiences and interventions for antipsychotic medication deprescribing among adult patients with critical illness. *Crit Care Explor*. 2022;4:E0806. DOI: [10.1097/CCE.0000000000000806](https://doi.org/10.1097/CCE.0000000000000806).
30. Kramer A. Status myoclonus: a nuanced predictor of poor outcome post cardiac arrest. *Neurocrit Care*. 2022;36:346–9.
31. Chakraborty T, Braksick S, Rabinstein A, Wijdicks E. Status myoclonus with post-cardiac-arrest syndrome: implications for prognostication. *Neurocrit Care*. 2022;36:387–94.
32. Ruijter BJ, Keijzer HM, Tjepkema-Cloostermans MC, et al. Treating rhythmic and periodic EEG patterns in comatose survivors of cardiac arrest. *N Engl J Med*. 2022;386:724–34. DOI: [10.1056/nejmoa2115998](https://doi.org/10.1056/nejmoa2115998).
33. Beretta S, Coppo A, Bianchi E, et al. Neurologic outcome of postanoxic refractory status epilepticus after aggressive treatment. *Neurology*. 2018;91:E2153–E2162. DOI: [10.1212/WNL.0000000000006615](https://doi.org/10.1212/WNL.0000000000006615).
34. Hoiland RL, Rikhray KJK, Thiara S, et al. Neurologic prognostication after cardiac arrest using brain biomarkers a systematic review and meta-analysis. *JAMA Neurol*. 2022;79:390–8. DOI: [10.1001/jamaneurol.2021.5598](https://doi.org/10.1001/jamaneurol.2021.5598).
35. Zhou SE, Maciel CB, Ormseth CH, Beekman R, Gilmore EJ, Greer DM. Distinct predictive values of current neuroprognostic guidelines in post-cardiac arrest patients. *Resuscitation*. 2019;139:343–50. DOI: [10.1016/j.resuscitation.2019.03.035](https://doi.org/10.1016/j.resuscitation.2019.03.035).
36. Benarous L, Gavaret M, Soda Diop M, et al. Sources of interrater variability and prognostic value of standardized EEG features in post-anoxic coma after resuscitated cardiac arrest. *Clin Neurophysiol Pract*. 2019;4:20–6. DOI: [10.1016/j.cnp.2018.12.001](https://doi.org/10.1016/j.cnp.2018.12.001).
37. Admiraal MM, van Rootselaar A, Hofmeijer J, et al. Electroencephalographic reactivity as predictor of neurological outcome in postanoxic coma: a multicenter prospective cohort study. *Ann Neurol*. 2019;86:17–27. DOI: [10.1002/ana.25507](https://doi.org/10.1002/ana.25507).
38. Duez CHV, Johnsen B, Ebbesen MQ, et al. Post resuscitation prognostication by EEG in 24 vs 48 h of targeted temperature management. *Resuscitation*. 2019;135:145–52. DOI: [10.1016/j.resuscitation.2018.10.035](https://doi.org/10.1016/j.resuscitation.2018.10.035).
39. Fatuzzo D, Beuchat I, Alvarez V, Novy J, Oddo M, Rossetti AO. Does continuous EEG influence prognosis in patients after cardiac arrest? *Resuscitation*. 2018;132:29–32. DOI: [10.1016/j.resuscitation.2018.08.023](https://doi.org/10.1016/j.resuscitation.2018.08.023).
40. Rossetti AO, Tovar Quiroga DF, Juan E, et al. Electroencephalography predicts poor and good outcomes after cardiac arrest. *Crit Care Med*. 2017;45:e674–e682. DOI: [10.1097/CCM.0000000000002337](https://doi.org/10.1097/CCM.0000000000002337).
41. Grippo A, Carrai R, Scarpino M, et al. Neurophysiological prediction of neurological good and poor outcome in post-anoxic coma. *Acta Neurol Scand*. 2017;135:641–8. DOI: [10.1111/ane.12659](https://doi.org/10.1111/ane.12659).
42. Westhall E, Rossetti AO, van Rootselaar AF, et al. Standardized EEG interpretation accurately predicts prognosis after cardiac arrest. *Neurology*. 2016;86:1482–90. DOI: [10.1212/WNL.0000000000002462](https://doi.org/10.1212/WNL.0000000000002462).
43. Amorim E, Rittenberger JC, Zheng JJ, et al. Continuous EEG monitoring enhances multimodal outcome prediction in hypoxic-ischemic brain injury. *Resuscitation*. 2016;109:121–6. DOI: [10.1016/j.resuscitation.2016.08.012](https://doi.org/10.1016/j.resuscitation.2016.08.012).
44. Alvarez V, Reinsberger C, Scirica B, et al. Continuous electrodermal activity as a potential novel neurophysiological biomarker of prognosis after cardiac arrest – a pilot study. *Resuscitation*. 2015;93:128–35. DOI: [10.1016/j.resuscitation.2015.06.006](https://doi.org/10.1016/j.resuscitation.2015.06.006).
45. Juan E, Novy J, Suys T, Oddo M, Rossetti AO. Clinical evolution after a non-reactive hypothermic EEG following cardiac arrest. *Neurocrit Care*. 2015;22:403–8. DOI: [10.1007/s12028-014-0095-4](https://doi.org/10.1007/s12028-014-0095-4).
46. Sivaraju A, Gilmore EJ, Wira CR, et al. Prognostication of post-cardiac arrest coma: early clinical and electroencephalographic predictors of outcome. *Intensive Care Med*. 2015;41:1264–72. DOI: [10.1007/s00134-015-3834-x](https://doi.org/10.1007/s00134-015-3834-x).
47. Noirhomme Q, Lehembre R, del Lugo Z, et al. Automated analysis of background EEG and reactivity during therapeutic hypothermia in comatose patients after cardiac arrest. *Clin EEG Neurosci*. 2014;45:6–13. DOI: [10.1177/1550059413509616](https://doi.org/10.1177/1550059413509616).
48. Finley Caufield A, Mlynash M, Eynhorn I, et al. Prognostication of ICU patients by providers with and without neurocritical care training. *Neurocrit Care*. 2022;37:190–9.
49. Shemie SD, Baker AJ, Knoll G, et al. Donation after cardiocirculatory death in Canada. *Can Med Assoc J*. 2006;175:S1–S1. DOI: [10.1503/cmaj.060895](https://doi.org/10.1503/cmaj.060895).
50. Weiss SL, Balamuth F, Hensley J, et al. The epidemiology of hospital death following pediatric severe sepsis. *Pediatr Crit Care Med*. 2017;18:823–30. DOI: [10.1097/PCC.0000000000001222](https://doi.org/10.1097/PCC.0000000000001222).
51. Dankiewicz J, Cronberg T, Lilja G, et al. Hypothermia versus normothermia after out-of-hospital cardiac arrest. *N Engl J Med*. 2021;384:2283–94. DOI: [10.1056/nejmoa2100591](https://doi.org/10.1056/nejmoa2100591).